Key result
Routine thromboprophylaxis with apixaban in myeloma patients treated with IMiD-containing regimens resulted in no venous thromboembolism and a 2.9% rate of arterial thrombosis at 6 months.
Why the study?
Does apixaban prevent arterial or venous thromboembolism in myeloma patients treated with IMiD-containing regimens?
Observational (n=70)
No
Does apixaban prevent arterial or venous thromboembolism in myeloma patients treated with IMiD-containing regimens?
Routine thromboprophylaxis with apixaban in myeloma patients receiving IMiD-containing regimens is associated with very low rates of venous and arterial thrombosis and a low risk of major bleeding.
Answers are grounded in this paper and cite their sources.
May support routine DOAC prophylaxis in IMiD-treated myeloma; extends VTE treatment evidence to prevention.
For patients with malignancy, there is increasing evidence for the use of direct oral anticoagulants (DOACs) in the treatment of venous thromboembolism (VTE) (Raskob et al, 2018), but their role in routine thromboembolic prophylaxis remains unclear. One group at high risk of both arterial and venous thrombosis is those with myeloma, particularly when treated with immunomodulatory drugs (IMiDs), such as thalidomide or lenalidomide (Leleu, 2012). Current guidelines suggest risk-adapted thromboprophylaxis with aspirin, low molecular weight heparin (LMWH) or warfarin (Palumbo & Palladino, 2012). Nevertheless, thrombosis rates of 5–8% are reported (Palumbo et al, 2011; Leleu, 2012) and in the recent presentation of data from the UK Myeloma XI study, up to 11·8% of patients experienced thromboembolism, most of whom took thromboprophylaxis as recommended (Bradbury et al, 2017). Current agents therefore have limited efficacy and present significant practical barriers, such as the need for subcutaneous injection or monitoring of the International Normalised Ratio, which limit compliance (Kahn et al, 2012). DOACs are promising due to their convenience and are known to be highly effective in other settings. There is some phase II trial data supporting routine prophylaxis of apixaban in patients with malignancy (Levine et al, 2012), and the Hokusai study of edoxaban for treatment of cancer-associated thrombosis included some patients with haematological malignancies treated with immunomodulatory drugs (Raskob et al, 2018). Here we report on our use of apixaban in myeloma patients treated with IMiDs. We previously performed an audit of 56 consecutive myeloma patients treated with IMiD-containing regimens between 2013 and 2014. Six of 29 patients (20·7%) receiving thromboprohylaxis with aspirin had VTE, and of 27 patients treated with heparins, 2 (7·4%) had VTE. These rates are broadly comparable with data in the literature and represent significant patient morbidity. In November 2014 our policy was changed such that apixaban became the standard thromboprophylaxis; the effect of this change is reported here. Our aim was to assess the safety and efficacy of apixaban as thromboprophylaxis in patients with multiple myeloma undergoing first line therapy with IMID-containing regimens. Consecutive myeloma patients who presented between 1 November 2014 and 31 December 2016 and who underwent first-line therapy with IMiD-containing regimens were included in this retrospective study. All patients received apixaban 2·5 mg twice daily for the first 4 months of therapy or until treatment was completed – whichever was shorter, and for a maximum of 6 months (unless another indication for anticoagulation was present, such as atrial fibrillation). Most patients therefore received apixaban prophylaxis throughout treatment but apixaban was not co-prescribed if IMiD therapy continued beyond this time. Patients with severe renal failure (creatinine clearance <15 ml/min) or thrombocytopenia <50 × 109/l received alternative anticoagulants and were excluded from this study. Patients already taking warfarin were also excluded. The primary outcome was the occurrence of arterial or venous thromboembolism within 6 months of treatment initiation. The incidence of bleeding episodes was recorded as follows: major bleeding according to International Society on Thrombosis and Haemostasis criteria (Schulman & Kearon, 2005), or any other significant bleeding requiring transfusion, invasive treatment, admission or otherwise deemed clinically relevant. Seventy consecutive and eligible patients were identified. Patient characteristics, including treatment regimen, are shown in Table 1. The median duration of apixaban therapy was 3·8 months (range 0·6–19·0) and the median duration of IMiD-based induction was 3·65 months (range 0·6–25·2). Thrombosis-free survival, censored for deaths during follow-up, is shown in Fig 1. No patients had venous thrombosis within 6 months of treatment initiation. Two patients (2·9%) had arterial thrombosis. One female patient had a non-haemorrhagic stroke at day 19 of lenalidomide-dexamethasone with no identified embolic source. She had no cardiovascular comorbidities. One male patient had a non-ST elevation myocardial infarction at day 23 of VTD (bortezomib, thalidomide, dexamethasone) with no previous diagnosis of ischaemic heart disease. He had stopped both thalidomide and apixaban 21 days previously due to a drug-induced rash. One patient (1·4%) had major bleeding – he had melaena during his 4th cycle of MPT (mephalan, prednisolone, thalidomide) that resolved on apixaban cessation. His platelet count dropped to 21 × 109/l during this episode and he required hospital admission for blood transfusion, but no bleeding point was identified at endoscopy. Five patients died in the 6 months following treatment initiation: none of these deaths were related to thrombosis or bleeding. This study reports real world experience of DOACs in a representative patient population treated with modern combination therapy, including frail elderly patients, those with prior thrombosis and others considered at high risk of thrombosis by standard criteria (Palumbo & Palladino, 2012). This study was limited by retrospective data collection, but outcomes could be reliably identified from the detailed electronic records of these consecutively presenting patients. In conclusion, we report on the use of apixaban for preventing IMiD-induced thrombosis in front line myeloma therapy. Rates of thrombosis appear to be very low with no cases of VTE identified and only 2 cases of arterial thrombosis. There was one episode of major bleeding in a patient with coexistent thrombocytopenia but no other clinically relevant bleeding was recorded. These toxicity rates compare favourably to historical and published data with other anticoagulants. Apixaban is a highly convenient, twice daily, oral tablet suitable for ambulatory treatment even in elderly and frail patients, and avoids the logistical and acceptability problems of subcutaneous injection of LMWH. Furthermore, it is cheaper than a course of dalteparin in our centre. Apixaban appears to be an attractive and safe option for routine thromboprophylaxis in myeloma patients treated with IMiD-containing regimens. NPFS and PHR designed the study; NS and AM collected and analysed data, PREJ provided access to patient data, NPFS wrote the manuscript. All authors critically revised the paper and approved the final version. The authors have no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Storrar et al. (2018) conducted an observational in Multiple myeloma (n=70). Apixaban was evaluated on Occurrence of arterial or venous thromboembolism within 6 months of treatment initiation. Routine thromboprophylaxis with apixaban in myeloma patients treated with IMiD-containing regimens resulted in no venous thromboembolism and a 2.9% rate of arterial thrombosis at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: